Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2016 Jul 13

PMID 27400937

Citations 50

Authors

Eric J Gratias

Jeffrey S Dome

Lawrence J Jennings

Yueh-Yun Chi

Jing Tian

James Anderson

Paul Grundy

Elizabeth A Mullen

James I Geller

Conrad V Fernandez

Elizabeth J Perlman

Affiliations

Soon will be listed here.

Abstract

Purpose: The goal of this study was to analyze the association of copy number gain of 1q in favorable-histology Wilms tumors (FHWTs) with event-free survival (EFS) and overall survival (OS) within each tumor stage and with 1p and 16q copy number loss and/or loss of heterozygosity.

Methods: Unilateral FHWTs from 1,114 patients enrolled in National Wilms Tumor Study-5 that were informative for 1p and 16q microsatellite markers (previously determined) and informative for 1q gain, 1p loss, and 16q loss using multiplex ligation-dependent probe amplification were analyzed.

Results: Eight-year EFS was 86% (95% CI, 84% to 88%) for the entire cohort. Of 1,114 patients, 317 tumors (28%) displayed 1q gain. Eight-year EFS was 77% for those with 1q gain and 90% for those lacking 1q gain (P < .001). Eight-year OS was 88% for those with 1q gain and 96% for those lacking 1q gain (P < .001). Within each disease stage, 1q gain was associated with inferior EFS (stage I, 85% v 95%; P = .0052; stage II, 81% v 87%; P = .0775; stage III, 79% v 89%; P = .01; stage IV, 64% v 91%; P = .001). OS was significantly inferior in patients with stage I (P < .0015) and stage IV disease (P = .011). With multivariable analysis, 1q gain was associated with an increased relative risk of relapse of 2.4 (P < .001), whereas 1p loss was not, despite significance on univariable analysis.

Conclusion: Gain of 1q is associated with inferior survival in unilateral FHWTs and may be used to guide risk stratification in future studies.

Citing Articles

Association between TRMT61B gene polymorphism and Wilms tumor susceptibility in Chinese children.

Huang X, Lu J, Deng C, Tang W, Wang X, Zhou H BMC Cancer. 2025; 25(1):260.

PMID: 39953499 PMC: 11827147. DOI: 10.1186/s12885-025-13670-7.

Predicting the prognosis of Wilms tumor by peripheral blood cells: a real-world study of more than 30 years.

Jie L, Qin-Lin S, Xiao-Mao T, Peng H, Zhuang-Cheng W, Zai-Hong H Ital J Pediatr. 2024; 50(1):245.

PMID: 39543678 PMC: 11566747. DOI: 10.1186/s13052-024-01805-8.

ZSTK474 targeting PIK3R3 inhibits the Wilms' tumor through G0 / G1 phase arrest.

Li M, Liu J, Jin L, Mi T, Zhang Z, Zhanghuang C PLoS One. 2024; 19(10):e0312178.

PMID: 39466763 PMC: 11515993. DOI: 10.1371/journal.pone.0312178.

Nephroblastoma in Older Adult: Case Report and Review of Literature.

Fernandez-Ferreira R, Torres-Zazueta J, Martinez-Medrano C, Melendez-Mendoza A, Tavares-Garcia S, Munoz Rubiano M Case Rep Oncol. 2024; 17(1):818-830.

PMID: 39144242 PMC: 11324259. DOI: 10.1159/000540279.

A comprehensive analysis of minimally differentially methylated regions common to pediatric and adult solid tumors.

Buckley D, Tew B, Gooden C, Salhia B NPJ Precis Oncol. 2024; 8(1):125.

PMID: 38824198 PMC: 11144230. DOI: 10.1038/s41698-024-00590-1.

References

Bown N, Cotterill S, Roberts P, Griffiths M, Larkins S, Hibbert S . Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group. Med Pediatr Oncol. 2002; 38(1):11-21. DOI: 10.1002/mpo.1258. View

Natrajan R, Williams R, Hing S, Mackay A, Reis-Filho J, Fenwick K . Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol. 2006; 210(1):49-58. DOI: 10.1002/path.2021. View

Lo K, Ma C, Bundy B, Pomeroy S, Eberhart C, Cowell J . Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma. Clin Cancer Res. 2007; 13(23):7022-8. DOI: 10.1158/1078-0432.CCR-07-1420. View

Schouten J, McElgunn C, Waaijer R, Zwijnenburg D, Diepvens F, Pals G . Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002; 30(12):e57. PMC: 117299. DOI: 10.1093/nar/gnf056. View

Segers H, van den Heuvel-Eibrink M, Williams R, van Tinteren H, Vujanic G, Pieters R . Gain of 1q is a marker of poor prognosis in Wilms' tumors. Genes Chromosomes Cancer. 2013; 52(11):1065-74. DOI: 10.1002/gcc.22101. View

Pezzolo A, Rossi E, Gimelli S, Parodi F, Negri F, Conte M . Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma. Neuro Oncol. 2008; 11(2):192-200. PMC: 2718991. DOI: 10.1215/15228517-2008-086. View

Huang C, Gadd S, Breslow N, Cutcliffe C, Sredni S, Helenowski I . Predicting relapse in favorable histology Wilms tumor using gene expression analysis: a report from the Renal Tumor Committee of the Children's Oncology Group. Clin Cancer Res. 2009; 15(5):1770-8. PMC: 2847352. DOI: 10.1158/1078-0432.CCR-08-1030. View

Kilday J, Mitra B, Domerg C, Ward J, Andreiuolo F, Osteso-Ibanez T . Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group.... Clin Cancer Res. 2012; 18(7):2001-11. DOI: 10.1158/1078-0432.CCR-11-2489. View

Hing S, Lu Y, Summersgill B, King-Underwood L, Nicholson J, Grundy P . Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Am J Pathol. 2001; 158(2):393-8. PMC: 1850292. DOI: 10.1016/S0002-9440(10)63982-X. View

10.

Grundy P, Telzerow P, Breslow N, Moksness J, Huff V, Paterson M . Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res. 1994; 54(9):2331-3. View

11.

Grundy P, Breslow N, Li S, Perlman E, Beckwith J, Ritchey M . Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005; 23(29):7312-21. DOI: 10.1200/JCO.2005.01.2799. View

12.

Williams R, Hing S, Greer B, Whiteford C, Wei J, Natrajan R . Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines. Genes Chromosomes Cancer. 2004; 41(1):65-79. DOI: 10.1002/gcc.20060. View

13.

Messahel B, Williams R, Ridolfi A, AHern R, Warren W, Tinworth L . Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study. Eur J Cancer. 2009; 45(5):819-26. DOI: 10.1016/j.ejca.2009.01.005. View

14.

Spreafico F, Gamba B, Mariani L, Collini P, DAngelo P, Pession A . Loss of heterozygosity analysis at different chromosome regions in Wilms tumor confirms 1p allelic loss as a marker of worse prognosis: a study from the Italian Association of Pediatric Hematology and Oncology. J Urol. 2012; 189(1):260-6. DOI: 10.1016/j.juro.2012.09.009. View

15.

Mackintosh C, Ordonez J, Garcia-Dominguez D, Sevillano V, Llombart-Bosch A, Szuhai K . 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene. 2011; 31(10):1287-98. DOI: 10.1038/onc.2011.317. View

16.

Termuhlen A, Tersak J, Liu Q, Yasui Y, Stovall M, Weathers R . Twenty-five year follow-up of childhood Wilms tumor: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2011; 57(7):1210-6. PMC: 4634648. DOI: 10.1002/pbc.23090. View

17.

Wittmann S, Zirn B, Alkassar M, Ambros P, Graf N, Gessler M . Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis. Genes Chromosomes Cancer. 2006; 46(2):163-70. DOI: 10.1002/gcc.20397. View

18.

Grundy R, Pritchard J, Scambler P, Cowell J . Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour. Br J Cancer. 1998; 78(9):1181-7. PMC: 2063011. DOI: 10.1038/bjc.1998.651. View

19.

Lu Y, Hing S, Williams R, Pinkerton R, Shipley J, Pritchard-Jones K . Chromosome 1q expression profiling and relapse in Wilms' tumour. Lancet. 2002; 360(9330):385-6. DOI: 10.1016/S0140-6736(02)09596-X. View

20.

Miwa T, Hirose Y, Sasaki H, Ezaki T, Yoshida K, Kawase T . Single-copy gain of chromosome 1q is a negative prognostic marker in pediatric nonependymal, nonpilocytic gliomas. Neurosurgery. 2010; 68(1):206-12. DOI: 10.1227/NEU.0b013e3181fd2c2e. View